Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

NCT03141632 on ClinicalTrials.gov · last registry update 2017-10-25

A small phase 2 — 17 participants, against a typical 110. The sponsor logged completion for May 2017. Primary outcome, as filed: Fluid intake.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: University Hospital, Basel, Switzerland
Sponsor type: Other
Enrollment: 17
Started: 2016-10-17
Primary completion: 2017-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Fluid intake

Conditions studied

Thirst · Water-Electrolyte Imbalance

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.